



ASTRO 2015  
technology meets  
patient care

57TH ANNUAL MEETING

MEETING DATES: OCTOBER 18-21, 2015

EXHIBIT DATES: OCTOBER 18-20, 2015

HENRY B. GONZÁLEZ CONVENTION CENTER

SAN ANTONIO

  
TARGETING CANCER CARE

# Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology/RTOG 9202

**C. A. F. Lawton**<sup>1</sup>, J. J. Dignam<sup>2</sup>, G. E. Hanks<sup>3</sup>, H. Lepor<sup>4</sup>, D. Grignon<sup>5</sup>,  
H. D. Brereton<sup>6</sup>, M. Bedi<sup>1</sup>, S. A. Rosenthal<sup>7</sup>, K. L. Zeitzer<sup>8</sup>, V. M. Venkatesan<sup>9</sup>,  
E. M. Horwitz<sup>3</sup>, T. M. Pisansky<sup>10</sup>, H. Kim<sup>11</sup>, M. B. Parliament<sup>12</sup>, Y. Kwok<sup>13</sup>,  
M. Roach III<sup>14</sup>, X. Lin<sup>15</sup>, and H. M. Sandler<sup>16</sup>

*<sup>1</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>2</sup>NRG Oncology Statistics and Data Management Center, Philadelphia, PA, <sup>3</sup>Fox Chase Cancer Center, Philadelphia, PA, <sup>4</sup>NYU Langone Medical Center, New York, NY, <sup>5</sup>Indiana University, Indianapolis, IN, <sup>6</sup>Northeast Radiation Oncology Center, Dunmore, PA, <sup>7</sup>Radiation Oncology Center, Sacramento, CA, <sup>8</sup>Einstein Medical Center, Philadelphia, PA, <sup>9</sup>London Regional Cancer Program, London, ON, Canada, <sup>10</sup>Mayo Clinic, Rochester, MN, <sup>11</sup>Wayne State University-Karmanos Cancer Institute, Detroit, MI, <sup>12</sup>Cross Cancer Institute - Alberta Health Services, Edmonton, AB, Canada, <sup>13</sup>University of Maryland School of Medicine, Baltimore, MD, <sup>14</sup>University of California, San Francisco, San Francisco, CA, <sup>15</sup>University of Chicago, Chicago, IL, <sup>16</sup>Cedars-Sinai Medical Center, Los Angeles, CA*

# Purpose

- To determine whether adding 2 years of adjuvant androgen-deprivation therapy (ADT) improves outcome for patients treated with ADT before and during radiation therapy (RT)
- This analysis will serve as a final update on outcomes and toxicities

# Methods

- Patients with biopsy-proven prostate cancer with cT2c-T4 disease and no extra pelvic lymph node involvement and prostate-specific antigen (PSA) < 150
- No distant metastasis
- KPS  $\geq$  70
- Institute Review Board (IRB) approval and informed consent signed
- No prior androgen deprivation therapy (ADT), chemo or radiation therapy (RT) allowed

# Treatment

- ADT started 2 months prior to RT and continued until RT completed
- ADT= flutamide (250 mg) orally 3x daily and goserelin (3.6 mg) injected subcutaneously monthly
- RT= conventional RT to the pelvis “4 field tech” to 44-46Gy ( $\geq$  4MV) followed by a “cone down” to the prostate to 65-70Gy (isocenter dose)
- Patients then randomized to no further ADT (short-term ADT) vs 24 additional months of monthly goserelin (long-term ADT)

# Results

- Study accrual dates: 6/92-4/95
- N=1554 patients registered, 1520 eligible w/ follow-up
- Median follow-up: 20 years
- Endpoints:
  - DFS (Disease Free Survival) = Primary Endpoint
  - OS (Overall Survival)
  - LP (Local Progression)
  - DM (Distant Mets)
  - BF (Biochemical Free Survival)<sup>1</sup>
  - DSS (Disease Specific Survival)
    - Death due to dz, treatment or unknown cause after DM
- Toxicity: No difference in urinary toxicity and minimal difference in bowel toxicity

<sup>1</sup>Phoenix definition

# Conclusions

- Compared to STAD, LTAD improves:
  - Disease Free Survival
  - Local Progression
  - Distant Metastasis
  - bNED Survival
  - Disease Specific Survival
- For LTAD, 10% risk reduction, ~3% absolute OS difference was not statistically significant
- **Patients who have locally advanced prostate cancer should receive radiation therapy and long term ADT**

# Discussion

- Comparison to other studies
  - EORTC 22961 – 6 months vs 36 months ADT:
    - 36 months improved Clinical Progression Free Survival
  - PCS IV (Canadian Trial) – 18 months vs 36 months:
    - No difference in OS, DSS or Distant Mets
  - DART01/05 GICOR Trial – 4 months vs 28 months + high dose RT:
    - OS, DM Free Survival & bNED improved with 28 months